Search
forLearn
5 / 34 resultslearn Hair Fibers
cosmetic product that temporarily makes hair appear thicker
learn Melatonin
hormone commonly taken for sleep aid has some topical benefits for hair
learn Estradiol
an estrogen promoting hair regrowth more commonly used in women
learn Bicalutamide
a nonsteroidal anti-androgen, most commonly used orally for women
Research
5 / 1000+ resultsresearch Cosmos Caudatus Kunth Leaf Extract Herbal Nanosuspension Formulations, Characterization, and Cytotoxicity Approach Against MCF-7 Breast Cancer Cells
Kenikir leaf extract nanosuspension may help inhibit breast cancer cell growth.
research Lipid Nanoparticles Based Cosmetics With Potential Application In Alleviating Skin Disorders
Lipid nanoparticles in cosmetics can effectively improve skin disorders and hair loss.
research Low-Dose Oral Minoxidil for Androgenetic Alopecia Is Not Associated with Significant Changes in Alcohol Consumption: A Retrospective Study of 21,971 Patients
Low-dose oral minoxidil does not significantly change alcohol consumption.
research Numbing Aesthetics: Taste and Tempers of Peppercorn, Mountain Pepper, Sansho
Peppercorn's rich cultural and historical significance was reduced to just a flavor by 20th-century chemists.
research Cortexolone 17a-Propionate: A New Antiandrogen Acting on Hair Dermal Papilla Cells for the Treatment of Androgenic Alopecia
Cortexolone 17a-propionate may be an effective new treatment for hair loss.
Community Join
5 / 1000+ resultscommunity Cosmo Pharma 2025 Investor Day Report
Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.
community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
community Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
community What’s your views on clascoterone 5% topical solution by cosmo
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.
community Breezula will hit the market in 2026, Cosmo Pharmaceuticals statement!
Breezula, a hair loss treatment, is expected to cost around $100 a month and is anticipated to be released in 2026. The effectiveness of Breezula is debated, with some suggesting it loses effectiveness over time and others arguing it maintains hair compared to baseline.